Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics shares tick higher as it hires new marketing manager

The firm's VMS Plus device is an accurate AI (artificial intelligence) tool for measuring whole-heart function
VentriPoint Diagnostics shares tick higher as it hires new marketing manager
The firm's technology allows medics to assess whole heart function

Shares in heart-imaging specialist VentriPoint Diagnostics Ltd (CVE:VPT) ticked higher on Thursday as it revealed it had a new marketing manager and gave an update on sales.

Jessica Naman will be responsible for marketing strategies that drive revenue, the med-tech group said. The firm's VMS Plus device is an accurate AI (artificial intelligence) tool for measuring whole-heart function using conventional ultrasound.

Naman will be leading the team in the pre-launch plan as the company showcases the next-generation system at EuroEcho 2018 in Milan, Italy, this December and will explore further opportunities in the future of 3-D heart analysis using conventional 2-D ultrasound technologies, said Ventripoint.

Proven track record

"With 15 years of experience in marketing for technology-based companies, most recently in the medical device industry, she brings a proven track record in the development and management of comprehensive marketing campaigns, which integrate a strategic approach to public relations, social media, conferences and events," said Desmond Hirson, president of Ventripoint.

Notably, Ventripoint said it had secured two new orders for its VMS Plus heart analysis products at leading hospitals in Germany and the USA.

A further cardiac centre in Canada is in the final stages of institutional sign-offs prior to issuing a purchase order, it added.

"The sales funnel has also expanded with 12 clinical studies being planned to show the merits of the VMS Plus approach to cardiac analysis in specific heart conditions, including pregnancy, stress tests, right heart failure, left heart failure, along with congenital heart disease in children and adults, and pulmonary hypertension," the company said in a regulatory statement.  

"In addition, the company's sales team will be delivering several presentations to pediatric cardiologists across North America and Europe on the VMS Plus products."

Shares added 3.13% to stand at $0.155 each.

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

test tubes
May 07 2019
Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves
Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use